We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
-$64.3M
Cap. Flow %
-6.32%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BTAI icon
BioXcel Therapeutics
BTAI
+$12.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.8M
3
GNRC icon
Generac Holdings
GNRC
+$11M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M
5
LLY icon
Eli Lilly
LLY
+$10.2M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 70.42%
2 Technology 5.67%
3 Consumer Discretionary 2.57%
4 Industrials 2.19%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
76
ADMA Biologics
ADMA
$1.96B
$2.58M 0.25%
1,081,292
-903,657
-46% -$2.48M
LONA
77
LeonaBio Inc
LONA
$66.3M
$2.07M 0.2%
+11,200
New +$1.87M
ORGS
78
DELISTED
Orgenesis Inc. Common Stock
ORGS
$2.01M 0.2%
39,880
-26,697
-40% -$1.45M
ALPN
79
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.74M 0.17%
+198,260
New +$1.81M
EPIX
80
DELISTED
ESSA Pharma
EPIX
$1.73M 0.17%
+250,000
New +$1.7M
CYPH
81
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.58M 0.16%
80,000
-8,000
-9% -$154K
ETNB
82
DELISTED
89bio
ETNB
$1.51M 0.15%
+58,939
New +$1.87M
DYN icon
83
Dyne Therapeutics
DYN
$4.7B
$1.41M 0.14%
+70,000
New +$1.54M
XCUR icon
84
Exicure
XCUR
$10.2M
$1.29M 0.13%
4,917
-7,750
-61% -$2.53M
NBSE
85
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.14M 0.11%
7,500
– –
OBIO icon
86
Orchestra BioMed
OBIO
$238M
$1.1M 0.11%
+100,000
New +$1.12M
PAND
87
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$1.09M 0.11%
+95,000
New +$1.62M
SEDG icon
88
SolarEdge
SEDG
$2.51B
$957K 0.09%
4,017
-42,000
-91% -$8.07M
NRIX icon
89
Nurix Therapeutics
NRIX
$2.41B
$785K 0.08%
+22,480
New +$567K
CRDF icon
90
Cardiff Oncology
CRDF
$66.5M
$568K 0.06%
+40,000
New +$264K
IMTXW
91
DELISTED
Immatics N.V. Warrants
IMTXW
$350K 0.03%
+100,000
New +$334K
PNT
92
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$288K 0.03%
+20,000
New +$273K
CRBP icon
93
CALL
Corbus Pharmaceuticals
CRBP
$166M
$141K 0.01%
2,617
-5,333
-67% -$966K
CLRB icon
94
Cellectar Biosciences
CLRB
$20.5M
$109K 0.01%
292
– –
OTLKW
95
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$17K ﹤0.01%
129,500
– –
AKBA icon
96
Akebia Therapeutics
AKBA
$354M
– –
-155,000
Closed -$2.1M
APRE icon
97
Aprea Therapeutics
APRE
$7.68M
– –
-7,914
Closed -$6.14M
BMY icon
98
Bristol-Myers Squibb
BMY
$133B
– –
-700,000
Closed -$41.2M
CAMT icon
99
Camtek
CAMT
$6.18B
– –
-37,184
Closed -$468K
CGEN icon
100
Compugen
CGEN
$222M
– –
-200,000
Closed -$3M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $64.3M in Q3 2020, closing 30 positions and reducing 28 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $41.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in BioXcel Therapeutics worth $11.7M.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.